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Abstract Cardiovascular diseases (CVDs) are the leading cause of death worldwide and represent a major problem of public
health. Over the years, life expectancy has considerably increased throughout the world, and the prevalence of
CVD is inevitably rising with the growing ageing of the population. The normal process of ageing is associated with pro-
gressive deterioration in structure and function of the vasculature, commonly called vascular ageing. At the vascular
level, extracellular matrix (ECM) ageing leads to molecular alterations in long half-life proteins, such as elastin and col-
lagen, and have critical effects on vascular diseases. This review highlights ECM alterations occurring during vascular
ageing with a specific focus on elastin fragmentation and also the contribution of elastin-derived peptides (EDP) in
age-related vascular complications. Moreover, current and new pharmacological strategies aiming at minimizing elastin
degradation, EDP generation, and associated biological effects are discussed. These strategies may be of major rele-
vance for preventing and/or delaying vascular ageing and its complications.
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1. Elastin in the vessel wall
The vessel wall extracellular matrix (ECM) is an active and dynamic
structure playing a fundamental role in regulating vascular function in
normal and pathophysiological conditions. The vascular ECM is com-
posed of collagens, elastin, and others ECM components such as glyco-
proteins, amorphous or soluble proteoglycans, growth factors, and
proteases sequestered in the matrix. ECM composition varies accord-
ing to the vessel wall tunicae (intima, media, and adventitia) and all along
the vascular tree.1 Collagens and elastin remains by far the most abun-
dant ECM proteins in the arterial wall.
Mature elastin is an insoluble and hydrophobic protein formed by
cross-linking of its soluble precursor, tropoelastin which is mainly pro-
duced by smooth muscle cells in the media and fibroblasts in the adven-
titia. An elastic fibre consists of fibrillin-rich microfibrils surrounding an
amorphous core of elastin (≈90% of elastic fibre content). Elastin is the
dominant ECM protein in the arterial wall, comprising 50% of its dry
weight.2 It allows vascular elasticity and recoil. In the tunica media, elas-
tic fibres are arranged in fenestrae sheets, or lamella, and circumferen-
tially aligned with smooth muscle cells. The number of lamellar units,
defined as an elastic lamella and adjacent smooth muscle cells, formed
the functional resilient unit of the arterial wall.3 Elastogenesis is
restricted to foetal and infancy, and mature elastin fibres remain for
lifespan. Indeed, its strong reticulation makes elastin a highly stable mol-
ecule with longevity comparable with human lifespan and any pro-
teolytic damage that does occur with age and disease is essentially
irreparable.4 Under pathological conditions, vascular and inflammatory
cells can, however, produce tropoelastin, but these tropoelastin mole-
cules fail to cross-link into mature elastic fibres.5
2. Vascular alterations occurring
with ageing
Ageing is a multifactorial process defined as the consequence of time-
dependent loss of function, resistance, and adaptability to stress in all
organs.6 Vascular ageing depends on both intrinsic and extrinsic me-
chanisms and is considered to be the result of time and gradual mod-
ifications of the vascular tree.7 The cellular and molecular mechanisms
involved in vascular ageing are complex and multifactorial.
During ageing and in the absence of observable vascular disease, sev-
eral changes in morphology and composition of conduit arteries occur
and contribute to decrease compliance, resilience, and increase stiff-
ness seen in aged conduit arteries8 (Figure 1). The migration and
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proliferation of medial smooth muscle cells, switching from a contract-
ile to a synthetic, proliferative, mitotic and migratory phenotype, causes
intima and media remodelling. This is accompanied by a progressive in-
crease in lumen diameter and lengthening of loosely tethered vessels,
such as the abdominal aorta, leading to tortuosity.9 In addition, changes
occur on the two most abundant matrix proteins present in the vessel
wall, collagen, and elastin, also contributing to increase vascular
stiffness. The collagen content increases with age, giving rise to a cor-
responding reduction in elastin amount and transferring the mechanical
load to collagen fibres, which are 100–1000 times stiffer than elastic
fibres. In addition to the age-related decrease in elastin content, the
structure of the elastic lamellae changes with age due notably to re-
peated mechanical loading and oxidative stress, showing clear signs
of fragmentation and rupture.8 At the same time, the remaining elastin
Figure 1 Molecular and cellular events occurring during vascular ageing. As depicted in the figure, ageing is associated with critical modifications of the
vascular wall with structural alterations, extracellular matrix remodelling, endothelial dysfunction, and deposits of lipids, calcium, and advanced glycation
end-products. All these events contribute to decrease compliance, resilience, and increase stiffness in aged conduit arteries. ECM, extracellular matrix;
MMP, matrix-metalloproteinases; NO, nitric oxide; AGE, advanced glycation end-products.
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become calcified10,11 while the collagen molecules progressively ac-
quire cross-links12 altering their structural and functional properties.
In addition, as arteries age or undergo pathological changes, the balance
between proteases and their inhibitors is lost and protease release in-
creases by the induction of matrix-metalloproteinases (MMP) gene ex-
pression, the activation of zymogens or the secretion of enzymes by
inflammatory cells. This chronic increase in MMP activation plays a cen-
tral role in age-associated arterial structural remodelling. Ageing has
been shown to enhance MMP-2/-7/-9/-14 activity in the aortic walls
of rodents, non-human primates, and humans.13
Finally, another determinant processes in vascular ageing are the in-
creased oxidative stress and inflammation. Indeed, ageing is associated
with a chronic, low-grade proinflammatory state and referred to
‘inflammaging’.14 Considerable data have demonstrated an increase in
systemic inflammatory markers during ageing in addition to proinflam-
matory transcription factors, integrins and proteases.15 Ageing also
generates excess of reactive oxygen species that compromise the vaso-
dilatory activity of nitric oxide, facilitate the formation of deleterious ra-
dicals,16 and play critical roles in vascular dysfunction.
3. Elastin fragmentation and
generation of elastin-derived peptides
The progressive deterioration in vascular structure and function with
medial degeneration, aortic stiffening and dilation, are the basis of the
so-called vascular aging continuum introduced by O’Rourke et al. in
2010.17 This continuum, which explains cardiovascular events occur-
ring with ageing in patients without classic cardiovascular risk factors,
highlights the fatigue then fracture of elastic lamellae in the proximal
aorta as the main trigger. As mentioned above, the very low turnover
rate of elastin in vivo leads to accumulation of age-related changes
caused by mechanical fracture, proteolysis, and calcification/glycation.
Mechanical fracture is due to fatigue failure caused by the pulsatile
wall strain (repetitive stretches and relaxations) experienced by the
aorta over the number of cardiac cycles throughout the lifetime. Elastic
fibres undergo more than 3 billion cycles of extension and recoil over
human lifespan. This purely mechanical issue is enhanced by patho-
physiological processes related to ageing such as calcification, glycation,
and lipid peroxidation. A positive correlation has been shown between
the extent of calcification and the degree of elastin fragmentation. Elas-
tin has several nucleation sites for apatite minerals favouring calcium ac-
cumulation.18,19 Moreover, aldehydes generated from peroxidation of
polyunsaturated fatty acids, particularly 4-hydroxynonenal, malondial-
dehyde, and acrolein, were described to link elastin and to induce a
loss of flexibility, and altered conformation leading to increased enzym-
atic digestion susceptibility.20 – 22 Finally, non-enzymatic cross-links of
elastin with advanced glycation end-products (AGE) and, more recent-
ly, carbamylation products have been also reported.23,24 All these ad-
ducts will contribute to elastin fragility and fragmentation that is further
amplified by inflammation and subsequent secretion of MMP13,25
(Figure 2).
Figure 2 Elastin remodelling during vascular ageing. During ageing, elastin is subject to remodelling and fragmentation. Different factors can contribute
to elastin fragility and rupture such as mechanical fracture, calcification, glycation, carbamylation, and peroxydation. In addition, these factors enhance
elastin susceptibility to proteolysis by specific elastases such as serine, cysteine, and matrix-metalloproteinases. Ela-2, neutrophil elastase; MMP, matrix-
metalloproteinases; EDP, elastin-derived peptides.
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3.1 Elastases
Elastases are endopeptidases that cleave insoluble and soluble elastin.
Elastases include serine-, cysteine- and metallo-proteinases26 (Figure 2).
The serine proteinases neutrophil elastase (Ela-2), cathepsin G, and
proteinase-3 (myeloblastin) are mainly expressed by polymorpho-
nuclear neutrophils and smooth muscle cells. Four members of the
cysteine cathepsin family (cathepsin L, S, K, and V) display elastinolytic
activity and are also mainly produced by macrophages and smooth
muscle cells. Finally, four MMP are known as elastases, gelatinase A
(MMP-2), matrilysin (MMP-7), gelatinase B (MMP-9), and macrophage
elastase (MMP-12). While gelatinases are expressed ubiquitously,
MMP-7 and MMP-12 are mainly produced by macrophages.26
Elastin degradation by elastases generates elastin-derived peptides
(EDPs). Among them, peptides harbouring a GxxPG consensus motif
(where x represents any amino acid) are bioactive because this se-
quence motif stabilizes a type VIII b-turn conformation.27 These bio-
active EDP are referred to as elastokines. The typical elastokine is
the VGVAPG peptide, a three-fold repetition sequence encoded by
exon 24 of human tropoelastin. Other bioactive GxxPG motifs,
GVYPG, GFGPG, and GVLPG,28 and longer elastokines have been re-
ported.29 For instance, MMP-7, -9, and -12 have been shown to gener-
ate the bioactive YTTGKLPYGYGPGG, YGARPGVGVGGIP, and
PGFGAVPGA peptides.29
3.2 The elastin receptor complex
Tropoelastin and EDP have been shown to bind avb3 and avb5 integ-
rins,30,31 a lactose insensitive receptor,32 and galectin-3.33 However,
the elastin receptor complex (ERC) is the most documented elastin re-
ceptor and possibly the most important EDP signalling transducer re-
ported so far. Indeed, elastin-binding protein (EBP) elicits most of their
biological effects following their interaction with the ERC. This recep-
tor has a singular composition: a peripheral 67 kDa subunit, named EBP
or spliced-galactosidase, and two membrane-associated proteins, a
55 kDa protective protein/cathepsin A (PPCA) and a 61 kDa neur-
aminidase (neuraminidase-1, Neu-1).34 EBP is a spliced variant of the
lysosomal b-galactosidase resulting through the deletion of exons
3 and 4 and the introduction of a frameshift. A second frameshift occurs
after the deletion of exon 6 restoring the initial frame. This spliced form
of b-galactosidase is devoid of enzymatic activity but retains the ability
to bind galactosugars (galactose, lactose, or chondroitin sulfate) that
are efficient antagonists of EDP binding. This singular splicing mechan-
ism generates a 32-residue sequence-specific of EBP containing the
elastin-binding site.35 The role of the PPCA subunit within the ERC is
still unknown but, by analogy to its function in the lysosome, it could
protect the two other subunits and thereby contribute to the struc-
tural integrity of the whole receptor complex. In contrast to PPCA,
the catalytic activity of Neu-1 is essential for signal transduction by
the ERC.36 Indeed, Neu-1 catalyses the local conversion of the GM3
ganglioside into lactosylceramide, a critical second messenger of ERC
signalling pathways.37
Binding of EDP to the ERC triggers a host of signalling events that de-
pends on the cell type (Figure 3). In fibroblasts, two signalling modules
are activated and converge to mitogen-activated protein kinase kinases
1/2 (MEK1/2) activation: the cyclic adenosine monophosphate (cAMP)/
protein kinase A (PKA)/B-Raf and Gi protein/phosphoinositide 3-kinase
g (PI3Kg)/Raf-1 modules.38 In smooth muscle cells, EBP-mediated cell
proliferation involves activation of Gi proteins concomitantly with
opening of calcium L-type channels.39 Finally, a PI3Kg/Akt/endothelial
nitric oxide synthase (eNOS)/nitric oxide (NO)/protein kinase G1
(PKG1) module involved in extracellular-regulated protein kinases
1/2 (ERK1/2) activation has been reported in endothelial cells.40
Importantly, a progressive age-dependent uncoupling of the ERC has
been shown to occur, impairing its transduction pathways.41 For
many years, the mechanisms involved in this uncoupling remained
elusive. Recently, our group has demonstrated that ERC uncoupling
observed during ageing involves a rise in basal Neu-1 activity to a level
too high to be modulated by EDP stimulation.42 Consequently, EDP-
mediated lactosylceramide production and Neu-1 sialidase activity
are reduced in ageing cells. These results, proposing that age-related
ERC uncoupling could originate from its inability to regulate Neu-1
activity and lactosylceramide production, are of crucial importance
considering the fact that EDP biological effects could not only vary
during ageing, but also that pharmacological approaches targeting this
peculiar receptor have to be adapted.
3.3 Challenges in the determination of EDP
levels in biologic fluids
Several attempts have been made to determine elastin fragmentation
products levels in biologic fluids of normal individuals and patients suf-
fering from vascular diseases. Elastin degradation was assessed either by
detecting circulating levels of elastin cross-links (i.e. desmosine/isodes-
mosine) or by elastin degradation products, whatever their nature.
These strategies were applied on serum, plasma, or urine samples
and mostly used immunological or colorimetric methods.43 – 47 The
use of HPLC coupled to mass spectrometry has been developed
more recently and seems to be suitable for monitoring desmosine/
isodesmosine levels.48 –51
The reported studies agreed that circulating EDP levels increase with
ageing and correlate with the progression of vascular diseases. Never-
theless, discrepancies exist in the reported EDP concentrations (ng/mL
to mg/mL range). This variation can be explained by the early observa-
tion made by Wei et al. on the selectivity of monoclonal antibodies
raised against soluble forms of elastin that depends on both the purifi-
cation protocol used for extracting fibrous elastin and the method used
for its solubilization.47 Consequently, there is currently no recognized
and standardized method at hand to quantify EDP levels in biologic
fluids. The current view is that EDP concentration in healthy subjects
should be in the nanograms per millilitre order45,52 and that higher con-
centrations (in the mg/mL order) could be reached in pathological si-
tuations.53 Even if this concentration seems extremely high, it has to
be emphasized that where elastin is degraded, the local concentration
of released EDP might be in that range.
Most EDP assay protocols aim at determining the global concentra-
tion of EDP. We now know that elastokines define a specific class of
EDP, i.e. biologically active matrix fragments able to modify cell behav-
iour. Undoubtedly, the availability of a robust method to quantify their
presence in biological fluids would be of great clinical value in the de-
tection and monitoring of vascular ageing and related complications.
4. Pathophysiological consequences
of elastin remodelling during
vascular ageing
As mentioned above, the wall of large conduit arteries, especially aorta,
thickens, loses elasticity, and stiffens with ageing. Arterial stiffness, as
measured by pulse wave velocity, is correlated with high blood
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pressure and is a causative factor in arterial hypertension.54 Elastin and
collagen determine the passive mechanical properties of large arteries
and any proteolytic degradation or chemical alterations that affects
elastin will modify its mechanical properties, thereby influencing arter-
ial stiffness and blood pressure. The contribution of elastin to arterial
stiffness has been extensively studied by the group of Mecham using
genetically modified mice.55 Eln2/2 and Eln+/2 mice have increased
left ventricular pressure, high blood pressure, and increased arterial
stiffness compared with wild-type mice.56,57 It was found that stiffness
is significantly increased in the Eln+/2 aorta by postnatal day (P) 7, while
systolic blood pressure is not significantly increased until P14, indicating
that increased large artery stiffness preceded the increase in blood
pressure in this animal model.58 Conversely, expression of the human
elastin gene in Eln+/2 mice which increases elastin amounts from 60
to 80% of normal levels reverses the changes in both arterial stiffness
and hypertension.59 However, a paradoxical increase in arterial elasti-
city has been observed in patients suffering from Williams–Beuren syn-
drome in which abnormalities of elastic fibres are observed.60,61
Williams–Beuren syndrome is a genetic disorder caused by the dele-
tion of one allele of the elastin gene and is associated with typical
cardiovascular abnormalities including arterial wall hypertrophy, supra-
valvular aortic stenosis, and systemic hypertension. Together with the
above-cited animal models, this human genetic disease demonstrates
that elastin has functions other than providing elasticity. It has been
shown that the increased proliferation of arterial smooth muscle cells,
in a quiescent contractile state, from arteries of patients suffering from
Williams–Beuren syndrome is due to decreased deposition of elas-
tin.62 Therefore, beyond elasticity, elastine also acts as an autocrine fac-
tor for smooth muscle cells.
Two other features of elastin that may contribute to increase arterial
stiffness are its ability to bind calcium and to cross-link adducts such as
AGE. Calcification of media of large arteries increases significantly with
ageing and there is a strong correlation between calcium content and
arterial stiffness in humans. Cumulative data from the literature showed
a gradual deposition of calcium phosphate minerals on elastic lamellae,
also known as medial elastocalcinosis. This was recently confirmed by
Khavandgar et al.63 in a model of Matrix Gla protein knockout
(MGP2/2) mice cross-bred with Eln+/2 mice. In these mice, elastin
haploinsufficiency impedes the progression of arterial calcification. Fi-
nally, elastin stiffness is also increased through cross-linking. Owing
Figure 3 Signalling pathways mediated by the elastin receptor complex and related pharmacological inhibition strategies. EDP binding to the elastin
receptor complex triggers signalling pathways. Moreover, the Neu-1 subunit can modulate the sialylation level of other membrane receptors and their
related signalling. Different pharmacological strategies to block the elastin receptor complex receptor signalling are depicted. EDP, elastin-derived pep-
tides; EBP, elastin-binding protein; PPCA, protective protein/cathepsin A; NEU-1, neuraminidase-1; DANA, 2,3-didehydro-2-deoxy-N-acetylneuraminic
acid; MEK1/2 mitogen-activated protein kinase kinases 1/2; ERK1/2 extracellular-regulated protein kinases 1/2; PKA, protein kinase A; PIP2, phosphati-
dylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PI3K, phosphoinositide 3-kinase.
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to its long biological life, elastin as well as collagen are exposed to vari-
ous non-enzymatic post-translational modifications that can contribute
to functional and structural alterations of their properties. For instance,
AGE-mediated cross-links of human aortic elastin increase with age-
ing23 and elevated concentrations of glycated EDP in sera of diabetic
patients with arterial hypertension have been reported.64 Recently, it
has been shown that elastin is also subject to carbamylation,24 another
non-enzymatic reaction involving binding of isocyanic acid to free ami-
no groups. Isocyanic acid is mainly formed by the spontaneous dissoci-
ation of urea but can also be derived from thiocyanate through
myeloperoxidase. Whether carbamylation of elastin affects its rigidity
and susceptibility due to proteolysis remains to be determined.
Proteolysis of elastin is another feature of elastin remodelling during
vascular ageing. In most of the studies reported so far, elastin degrad-
ation and/or presence of EDP have shown detrimental effects on vas-
cular complications associated with ageing. By cross-breeding MMP
(MMP-2, -7, -9, -12) or cathepsin (K, L, S)-deficient mice with
LDLR2/2 or ApoE2/2 mice, two established models of atherogen-
esis,65,66 elastin degradation was shown to contribute to progression
of atherosclerosis. Contradictory data have been reported on plaque
stability, but elastin fragmentation may well play important role in pla-
que destabilization and rupture, as recently reported by two recent
studies from a same group.67,68 By cross-breeding ApoE2/2 mice
with mice containing a heterozygous mutation (C1039G+/2) in the
fibrillin-1 gene that exhibit impaired elastin structure and elastin frag-
mentation in the vascular wall, increased arterial stiffness, development
of highly unstable plaques with intraplaque neovascularization and pla-
que rupture have been reported.67,68 Direct evidence for the involve-
ment of EDP in the progression of atherosclerosis has been recently
reported by Gayral et al.69 Chronic injections of EDP or VGVAPG
into LDLR2/2 or ApoE2/2 mice were shown to increase atheroscler-
otic plaque size formation in these mice. The absence of PI3Kg in bone
marrow-derived cells prevented EDP effects of atherosclerosis in vivo as
well as EDP-mediated monocyte migration and reactive oxygen species
(ROS) production in vitro. In addition, degradation of elastic lamellae in
LDLR2/2 mice fed with an atherogenic diet correlates with athero-
sclerotic plaque formation. Using a model presenting a drastic reduc-
tion of Neu-1 activity,70,71 the ERC was shown to be essential to
atherogenesis in condition of endogenous elastin fragmentation. The
defect in Neu-1 activity in this model was correlated with a decrease
in monocyte and lymphocyte infiltration, clearly demonstrating the
role of this receptor complex in inflammatory processes of atherogen-
esis and the involvement of endogenous EDP. Another critical player
that contributes to atherosclerotic plaque development and progres-
sion are vascular smooth muscle cells.72 In this context, EDP have
been shown to stimulate in vitro smooth muscle cell migration and pro-
liferation39,73 and to differentiate rat aortic smooth muscle cells74 and
rat dermal fibroblasts75 into cells exhibiting an osteoblast-like pheno-
type. These phenotypic transitions mediated by EDP are potentiated
by transforming growth factor-b1 (TGF-b1) and could influence vascu-
lar calcification occurring during ageing.
Destruction of elastic fibres also play a predominant role in abdom-
inal aortic aneurysm (AAA) development, a chronic degenerative vas-
cular condition that is associated with ageing.76 The pathophysiology of
aortic aneurysms is complex and characterized by an infiltration of the
vessel wall by lymphocytes and macrophages, destruction of elastin and
collagen in the media and adventitia, loss of smooth muscle cells with
thinning of the media, and neovascularization. The infusion of porcine
pancreatic elastase into rat aortas, in addition to the well-known
angiotensin II and calcium chloride animal models, have been extensive-
ly used as a model of AAA and revealed that destruction of elastic fibres
play a critical role in AAA development. These detrimental effects in
AAA development were also demonstrated using MMP-deficient
mice such as MMP-2 and MMP-9, and more recently using mice defi-
cient in cathepsin S,77 K,78 and L.79 In these cathepsin-deficient mice,
the significant reduction in AAA development was associated with de-
creased in elastin fragmentation, cell proliferation and apoptosis, in-
flammatory cell infiltration, protease expression, and angiogenesis to
different extent according to the cathepsin deficiency. Several studies
based on human cohorts have proposed that circulating EDP could
be used as a biomarker predicting AAA progression.80 These EDP
may be important signals to a variety of cells involved in the develop-
ment of AAA, stimulating chemotaxis and MMP production. Direct evi-
dence for the involvement of EDP has been provided by using the
VGVAPG peptide and BA4, a blocking antibody directed against the
EBP recognition sequence GxxPG. Hance et al. were among the first
to demonstrate in vitro that EDP released from human AAA tissues
can attract monocytes through the ERC. They showed that AAA-
derived monocyte/macrophage chemotactic activity was eliminated
by competition with the VGVAPG peptide and decreased by about
40% in the presence of BA4.81 Comparable results were obtained using
aortic extracts from mgR/mgR mice, a mouse model of Marfan syn-
drome.82 Marfan syndrome is an autosomal-dominant inherited dis-
order of connective tissue caused by mutations in the gene for
fibrillin-1, with prominent clinical manifestations in the cardiovascular,
skeletal, and ocular systems. Aneurysm formation and aortic dissection
remain the most life-threatening complications of Marfan syndrome.
Using this fibrillin-1 hypomorphic mouse model (mgR/mgR), the
same group recently showed direct involvement of EDP and the ERC
in the development of AAA.83 Intraperitoneal injections of BA4 were
shown to reduce MMP-2 and MMP-9 expression, as well as elastin frag-
mentation and macrophage infiltration in the aorta of treated animals.
New emerging effects of EDP have recently been reported in
diabetes mellitus. Diabetes mellitus is a chronic metabolic disease asso-
ciated with hyperglycaemia, macro- and micro-vascular complications,
and considered as a major risk factor for CVD.84 Type 2 diabetes is the
most common form of diabetes mellitus and typically considered as
adult-onset diabetes. Type 2 diabetes is characterized by hypergly-
caemia and peripheral insulin resistance mostly caused by reduced in-
sulin sensitivity in skeletal muscle, adipose tissue, and liver. Diabetes
mellitus accelerates vascular ageing and is associated with extensive
vascular ECM remodelling. Increased MMP plasma concentrations,
such as MMP-2 and MMP-9,85 and serum levels of EDP and glycated
EDP have been reported in diabetic patients.64,86,87 Indeed, the pres-
ence of EDP in the blood leads to the formation of anti-elastin anti-
bodies, and both are associated with the development of diabetic
vascular complications.64,86 – 89 How elastin fragmentation and EDP
contribute to the development of diabetes mellitus and/or vascular
complications associated with diabetes mellitus remains unknown so
far. Recently, insulin resistance has been linked to the expression of
cathepsin S,90 neutrophil elastase,91 and imbalance between serum
levels of neutrophil elastase and the neutrophil elastase inhibitor
a1-antitrypsin,92 raising the possibility of EDP involvement in the devel-
opment of insulin resistance. This hypothesis was confirmed in wild-
type mice in which administration of EDP and the VGVAPG peptide
was shown to increase hyperglycaemia and to trigger insulin resist-
ance.93 Importantly, these effects were blocked by the neuraminidase
inhibitor 2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA) or
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chondroitin sulfate. In addition, Blaise et al.93 showed that EDP trigger
interaction between Neu-1 and the insulin receptor. This EDP-
mediated interaction results in lower sialylation and phosphorylation
levels of the insulin receptor and decreased insulin receptor signalling.
Taken together, these data suggest that EDP may be involved in the in-
sidious development of insulin resistance occurring during ageing
through the regulation of insulin receptor signalling by the Neu-1 sub-
unit of the ERC.
Finally, another emerging effect of EDP came from the work of
Kawecki et al.94 on thrombosis. Vascular ageing is associated with
haemostasis dysregulation and increased thrombosis tendency.95 In
their study, Kawecki et al. have reported, for the first time, that EDP
decrease human platelet aggregation in whole blood induced by differ-
ent weak and strong platelet agonists and that both EDP and the
VGVAPG peptide strongly reduce thrombus formation in a mouse
model of thrombosis induced by chemical injury. Moreover, EDP and
VGVAPG also prolonged tail-bleeding times.94 This unexpected regu-
latory role of EDP on thrombosis seems to rely on a dual mechanism
involving effects on platelets that express a functional ERC able to trig-
ger an increase of platelet sialidase activity, and on the ability of EDP to
disrupt plasma von Willebrand factor interaction with collagen by spe-
cifically binding to collagen fibres.94 This latter correlated with reduced
platelet interaction with collagen under flow conditions and therefore
may have critical impact on platelet adhesion with the vessel wall in vivo.
Whether EDP also affect clotting and fibrin formation remains to be
determined. These effects of EDP on thrombosis, which remain to
be further investigated, in addition to their reported proangiogenic
roles, may have important consequences on the AAA outcome and
atherosclerosis progression because neovascularization and intrapla-
que haemorrhage have been associated with increased risk of plaque
rupture. This hypothesis seems to be supported by the phenotype of
the ApoE2/2/fibrillin-1C1039G+/2 mice. As previously mentioned,
these mice that exhibit impaired elastin structure and severe elastin
fragmentation show highly unstable plaques with intraplaque neovascu-
larization and plaque rupture.67,68
5. Pharmacological strategies
Limiting or blocking the deleterious effects of EDP during age-related
vascular complications can be achieved using several strategies: (i) tar-
geting elastases to limit elastin fragmentation and EDP generation; (ii)
blocking the interaction between EDP and the ERC; (iii) inhibiting
Neu-1-associated sialidase activity; and (iv) blocking downstream
signalling molecules involved in ERC signal transduction.
5.1 Inhibiting elastases
Elastases are targets of high therapeutic potential in a large number of
diseases. These elastin-degrading enzymes are organized as inter-
connected proteolytic cascades regulating each other. Consequently,
targeting these enzymes is challenging. Moreover, due to their involve-
ment in the regulation of several tissue functions, their inhibition often
results in adverse side effects. Current examples of elastase inhibition
strategies are briefly described below.
Human neutrophil elastase plays important role in ECM remodelling
in response to injury. This protease can be rapidly released with
proteinase-3 by neutrophil degranulation and is at the crossroad of nu-
merous regulatory pathways, notably in the vascular context.96 Syn-
thetic small molecule inhibitors have been developed to inhibit its
activity and clinical studies have focused on inflammatory lung diseases.
Unfortunately, those inhibitors have shown limited effects. New strat-
egies based on endogenous inhibitors of human neutrophil elastases
are now considered. Data obtained from two serpins, secretory leuco-
cyte protease inhibitor (SLPI) and elafin, suggest that these natural
inhibitors may have therapeutic potentials.96 For instance, elafin-
overexpressing mice had reduced neutrophil infiltration of cardiac tis-
sue, decreased left ventricular fibrosis and infarct size in a myocardial
ischaemia model.97 Likewise, smooth muscle cell proliferation and in-
flammatory cells invasion were suppressed in a model of arterial injury
using mice overexpressing elafin.98 These preclinical observations sug-
gested that elafin could be a good candidate to prevent elastase contri-
bution to deleterious inflammation after major surgery. Consequently,
elafin administration was evaluated in clinical trials aiming at limiting
elastase involvement. Unfortunately, a recent report shows that this
strategy gives limited results when elafin is administrated as a single
dose.99 Consequently, continuous delivery of the elastase inhibitor
or higher dose could be required to reach an efficient protective effect.
Inhibition of MMP elastases has been mostly considered in the con-
text of cancer research as these enzymes are critically involved in tu-
mour invasion. Considerable efforts have been made to develop
potent inhibitors, but results have been disappointing due to important
undesired effects. However, the development of specific MMP inhibi-
tors is an absolute priority.100 The current inhibitor design considers
the targeting of secondary binding sites to improve inhibition specifi-
city. For instance, small molecules have been developed to bind the
collagen-binding domain of MMP-2 and MMP-9. In addition, current
data show that a strategy based on exosite binding is promising as
selectivity is greatly enhanced.100
As mentioned previously, cathepsins are also potent elastases.
Therapeutic targeting of this enzyme family has mainly focused on ca-
thepsin K, the main bone-degrading protease in the osteoclasts and
thereby the major target for osteoporosis. Potent peptide-derived in-
hibitors displaying a reversible binding nitrile or ketone warhead were
synthesized.101 For further details on cathepsin inhibitors, the reader is
referred to the excellent review of Fonovic and Turk102 describing the
current existing inhibitors. In the context of vascular wall remodelling,
cathepsin S targeting seems to be the most promising target.103
5.2 Blocking EDP/ERC interaction
Blocking EDP binding to the EBP subunit of the ERC can be achieved
either using the V14 peptide or galactosides (Figure 3). The V14 peptide
(VVGSPSAQDEASPL) mimics the EBP sequence on which EDP bind.
Consequently, the V14 peptide has the potential to trap circulating
EDP, thereby blocking their biological effects.104,105 Another possibility
is to use galactosugars, lactose, or chondroitin sulfate, because their
interaction with EBP leads to shedding of EBP from the ERC and block-
ing of the corresponding signalling pathways. These compounds were
used to demonstrate the beneficial effects of EDP in heart protection
against ischaemia/reperfusion injury104 and in tissue repair.106 Although
the V14 peptide and galactosugars allowed better understanding in the
field of EDP biology, their selective delivery at the site of vascular injury
remains an issue.
5.3 Inhibiting Neu-1 sialidase activity
DANA is currently used as a sialidase inhibitor to selectively block
ERC-mediated signalling.42,69,93 However, this compound is not specif-
ic to Neu-1 and inhibits all sialidases, precluding its therapeutic use. An
attempt was made to design and synthesize inhibitors for human neur-
aminidases, but the results were not satisfactory.107 Indeed, selectivity
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was not achieved, most probably because the structures of human sia-
lidases are not fully described. Recently, O’Shea et al.108 used oseltami-
vir phosphate (Tamifluw) to target Neu-1 and block cancer cell survival
in human pancreatic cancer with acquired chemoresistance. This study
suggests that Tamifluw, used in the treatment of influenza infection,
could possibly be used to selectively block Neu-1. Nevertheless, this
possibility has still to be validated in a vascular injury context.
5.4 Blocking ERC-mediated signalling
pathways
The biological effects mediated by the ERC could be the resulting of
either direct and/or indirect actions (Figure 3). Direct effects are the re-
sults of lactosylceramide production in the cell following Neu-1 activa-
tion. Lactosylceramide is considered as a critical proximal second
messenger in ERC signalling and blocking lactosylceramide production
and related signalling pathways will block ERC effects. In this context, a
downstream signalling protein involved in ERC signal transduction is
PI3Kg.38,69 This class IB PI3K is largely expressed in inflammatory
cells109 but has also been identified in cells of the cardiovascular system,
particularly in endothelial cells110 and smooth muscle cells.111 This ori-
ginal expression pattern, different from other class of PI3K, places this
protein as a good candidate for drug targeting in CVD.109,112 In this
context, our team has played a large part in determining the in vitro
and in vivo immuno-modulatory functions of PI3Kg in arterial patholo-
gies of atherosclerosis113 and restenosis.114 By driving the monocyte
response to EDP, we recently identified that PI3Kg is a key signalling
protein involved in EDP-induced atherosclerosis in vivo.69 Our work re-
veals one of the possible mechanisms by which PI3Kg drives athero-
sclerosis. The role of PI3Kg downstream of ERC in the modulation
of the inflammatory functions of immune cells in atherogenesis raises
the specific role of this pathway in the complications of atherosclerosis
such as neointima formation in arterial damage after angioplasty or
intra-stent neoatherosclerosis development. Indeed, the importance
of EDP signalling remains to be elucidated in these arterial diseases,
and such results will reinforce the use of specific PI3Kg inhibitors in
this pathological context. Nevertheless, specific attention should be
paid to the development of safer PI3Kg inhibitors to follow new ther-
apeutical strategies in the prevention of CVD. Another important as-
pect to elucidate is the molecular mechanism explaining how PI3Kg
is activated downstream of the ERC since this kinase was demonstrated
to be specifically activated by downstream G protein-coupled
receptors.
Indirect effects could originate from Neu-1 activity on adjacent
membrane receptors (Figure 3). Indeed, during the last decade,
Neu-1 has been shown to be involved in the modulation of insulin re-
ceptor signalling93 and regulation of toll-like receptor 4 (TLR4),115
tropomyosin receptor kinase A (Trk A),116 PDGF subunits BB
(PDGF-BB) and insulin-like growth factor (IGF) receptors,117 epi-
dermal growth factor (EGF) and mucin 1 (MUC1) receptors,118 and
more recently platelet endothelial cell adhesion molecule
(PECAM-1), also known as cluster of differentiation 31 (CD31).119
It is not excluded that Neu-1 can also modify G protein-coupled re-
ceptors leading to PI3Kg recruitment to the plasma membrane. Con-
sequently, Neu-1 now emerges not only as a catabolic enzyme but
also as a key factor in cell signalling regulation.120 Efforts are now
made to understand how Neu-1 interacts with these membrane pro-
teins in order to conceive new strategies aiming at selectively block-
ing these interactions.
6. Concluding remarks and future
directions
Considered for a long time as an inert supporting network for cells,
the vascular ECM is definitely an active and dynamic structure playing
central role in vascular ageing and related complications. Over the
last decade, elastin fragmentation and generation of EDP have
emerged as major contributors of vascular ECM remodelling and re-
lated diseases occurring with ageing. Owing to their pathophysio-
logical importance, limiting or blocking the deleterious effects of
elastin fragmentation and EDP may represent promising therapeutic
targets. As mentioned previously, different strategies can be consid-
ered: the design of specific and selective elastase inhibitors to limit
elastin fragmentation, or compounds that can block the interaction
between EDP and the ERC, Neu-1 activity or intracellular proteins
involved in ERC signalling pathways (Figure 3). However, a large
number of questions remain to be answered. For instance, our un-
derstanding on the various MMP networks and their mutual relation-
ships is incomplete. Furthermore, how the expression of elastases
changes during ageing and the progression of vascular complications
needs to be addressed.
Another unresolved question is the organization and stoichiometry
of the ERC at the plasma membrane. For instance, the presence of a
plasma membrane-bound Neu-1 regulating a plethora of membrane re-
ceptors by desialylation has been consistently documented from the
last 10 years. However, Neu-1 is, by definition, a lysosomal sialidase
and current structural data cannot account for such membrane local-
ization. How the different subunits of the ERC organize within the plas-
ma membrane will undoubtedly help in the design of specific inhibitors
of the receptor.
It is also unclear how the progressive age-dependent uncoupling of
the ERC occurs.41 As previously mentioned, we recently demonstrated
that this age-related ERC uncoupling could originate from its inability to
regulate Neu-1 activity and lactosylceramide production in cultured
human fibroblasts.42 If this phenomenon could also apply for endothe-
lial cells, smooth muscle cells and circulating cells remains to be shown.
Finally, the biological effects of elastin degradation products described
in this review highlight the influence of matrix-directed proteolysis dur-
ing ageing. Hence, it can be reasonably expected that remodelling and
proteolytic fragments of another vascular ECM proteins could also play
a significant role in vascular ageing and related complications.
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